Effects of sitagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor, on blood glucose and plasma incretin and insulin responses to small intestinal glucose infusion, in healthy lean and obese subjects, and alone or in combination with metformin in patients with type 2 diabetes mellitus.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 14 Nov 2013 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 14 May 2009 New trial record